dph1 Antibody

What tissues express DPH1 and how should positive controls be selected?

DPH1 demonstrates broad tissue expression, which provides researchers with multiple options for positive controls. The protein is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, mammary gland, colon, small intestine, testis, and ovary . When designing experiments with DPH1 antibodies, researchers should consider using tissues with high expression levels as positive controls.

For immunohistochemistry applications, liver and kidney tissues generally provide reliable positive controls due to their consistent DPH1 expression. Standardized protocols suggest tissue fixation in 10% neutral buffered formalin followed by paraffin embedding, with sections cut at 4-6μm thickness for optimal staining results.

How can specificity of DPH1 antibodies be validated?

Validating antibody specificity is crucial for obtaining reliable research results. For DPH1 antibodies, a multi-pronged validation approach is recommended:

• Western blot analysis showing a single band at the expected molecular weight (48.1 kDa)

• Immunostaining pattern consistent with known subcellular localization (nucleus and cytoplasm)

• Reduced or absent signal following DPH1 gene knockdown or knockout

• Comparison across multiple antibodies targeting different epitopes of DPH1

• Verification using recombinant DPH1 protein as a positive control

Researchers should be aware that some commercially available DPH1 antibodies have been extensively validated through the Human Protein Atlas project, which provides immunohistochemistry and immunofluorescence data accessible through their online portal .

What are the optimal experimental conditions for DPH1 antibody in Western blotting?

For optimal Western blot results with DPH1 antibodies, the following protocol parameters are recommended:

• Sample preparation: Lyse cells in RIPA buffer supplemented with protease inhibitors

• Protein loading: 20-50 μg of total protein per lane

• Gel percentage: 10-12% SDS-PAGE for optimal separation

• Transfer conditions: Wet transfer at 100V for 1 hour or 30V overnight

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody: Dilute according to manufacturer's recommendation (typically 1:500-1:2000)

• Incubation: Overnight at 4°C with gentle rocking

• Secondary antibody: Anti-rabbit HRP conjugate (1:5000-1:10000)

• Detection: Enhanced chemiluminescence (ECL) substrate

Expected results include a distinct band at approximately 48.1 kDa, though minor additional bands may appear depending on the specificity of the antibody and post-translational modifications of the protein.

How can researchers use ADP-ribosylation assays to functionally assess DPH1 variants?

ADP-ribosylation (ADPR) assays provide a powerful functional readout for DPH1 activity by measuring its contribution to diphthamide synthesis. This approach is particularly valuable when investigating the pathogenicity of DPH1 variants:

• Principle: DPH1 catalyzes the first step in diphthamide biosynthesis, which is required for the ADP-ribosylation of eEF2 by diphtheria toxin

• Methodology: Cell lysates expressing wild-type or variant DPH1 are incubated with purified diphtheria toxin fragment A and radiolabeled NAD+

• Analysis: The level of ADP-ribosylated eEF2 is quantified via SDS-PAGE followed by autoradiography

• Interpretation: Reduced ADP-ribosylation indicates compromised DPH1 function

Recent research has used this approach to validate the pathogenicity of multiple DPH1 variants, including p.(Leu234Pro), p.(Ala411Argfs*91), p.(Leu164Pro), p.(Leu125Pro), and p.(Tyr112Cys) . The results demonstrated a correlation between the severity of functional impairment and clinical manifestations.

How can structural modeling complement antibody-based studies of DPH1 variants?

Structural modeling provides critical insights into the molecular mechanisms by which DPH1 variants affect protein function. When combined with antibody-based detection methods, this approach enables a comprehensive characterization of variant effects:

• Homology modeling: A model of the human DPH1-DPH2 heterodimer can be constructed based on available crystal structures of homologous proteins

• Molecular dynamics simulations: These can reveal how variants affect:

  • The size and accessibility of the catalytic site

  • Protein stability and flexibility

  • Interactions between DPH1 and DPH2 subunits

• Integration with functional data: Correlate structural changes with results from ADPR assays and antibody-based detection methods

Research has demonstrated a correlation between loss of activity, reduced size of the opening to the catalytic site, changes in the size of the catalytic site, and clinical severity of DPH1 syndrome . This integrated approach provides mechanistic explanations for experimental observations and can guide therapeutic development.

What experimental approaches can distinguish between DPH1's tumor suppressor and oncogenic roles?

The dual nature of DPH1 as both a tumor suppressor and potential oncogene presents an intriguing research question. To investigate this dichotomy, researchers can employ the following methodological approaches:

• Cell line-specific expression analysis: Quantify DPH1 expression across various cancer cell lines using validated antibodies in Western blot and immunohistochemistry

• Functional studies with genetic manipulation:

  • Knockdown studies using siRNA or shRNA

  • Overexpression studies with wild-type and mutant DPH1

  • Analysis of resulting changes in cell viability, invasion, and proliferation

• miRNA regulatory network analysis:

  • Bioinformatic prediction of miRNAs targeting DPH1

  • Luciferase reporter assays to validate direct targeting

  • Correlation analysis between miRNA levels and DPH1 expression

Research in colorectal cancer has identified an unexpected oncogenic role for DPH1, with miR-218-5p directly regulating DPH1 expression. Loss of this miRNA was found to drive the oncogenic activity of DPH1 in colorectal cancer cells . These findings highlight the importance of tissue context in determining DPH1 function.

How can DPH1 antibodies be utilized to study DPH1 syndrome?

DPH1 syndrome is an ultra-rare neurodevelopmental disorder characterized by variable developmental delay, short stature, dysmorphic features, and sparse hair . DPH1 antibodies serve as critical tools for investigating this condition:

• Expression analysis in patient samples:

  • Immunohistochemistry or immunofluorescence to assess DPH1 localization and expression levels

  • Western blot quantification of DPH1 protein levels

• Variant characterization:

  • Immunoprecipitation of wild-type and variant DPH1 proteins

  • Analysis of interactions with DPH2 and other binding partners

  • Assessment of protein stability and turnover

• Functional studies:

  • Immunodetection of diphthamide-modified eEF2

  • Correlation with ADPR assay results

By combining antibody-based detection with functional assays and structural modeling, researchers can establish genotype-phenotype correlations and gain insights into the pathophysiology of DPH1 syndrome .

What considerations are important when optimizing immunohistochemistry for DPH1 detection in different pathological tissues?

Optimizing immunohistochemistry (IHC) protocols for DPH1 detection requires careful consideration of several factors:

• Tissue preprocessing:

  • Fixation: 10% neutral buffered formalin for 24-48 hours

  • Antigen retrieval: Citrate buffer (pH 6.0) or EDTA buffer (pH 9.0), with heat-induced epitope retrieval

• Antibody selection:

  • Different epitopes may be accessible in different tissues

  • Polyclonal antibodies often provide broader epitope recognition

• Protocol optimization:

  • Antibody dilution: Typically 1:20 to 1:200 for IHC applications

  • Incubation time and temperature: Overnight at 4°C or 1-2 hours at room temperature

  • Detection system: DAB chromogen with hematoxylin counterstain

• Controls:

  • Positive tissue controls (based on known expression patterns)

  • Negative controls (omission of primary antibody)

  • Comparison with mRNA expression data

Researchers should conduct titration experiments to determine optimal antibody concentrations for specific tissue types and fixation conditions. Validation across multiple antibodies targeting different epitopes can provide additional confidence in staining specificity.